NervGen Pharma Corp (NGEN)

Currency in USD
1.67
0.00(0.00%)
Closed·
1.69+0.02(+1.20%)
·
Trading near 52-week Low
NGEN is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
1.591.70
52 wk Range
1.596.30
Key Statistics
Prev. Close
1.67
Open
1.65
Day's Range
1.59-1.7
52 wk Range
1.59-6.3
Volume
858.35K
Average Volume (3m)
907.04K
1-Year Change
-39.2727%
Book Value / Share
0.05
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
NGEN Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
10.60
Upside
+534.99%
Members' Sentiments
Bearish
Bullish
ProTips
Suffers from weak gross profit margins

NervGen Pharma Corp News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Buy
Moving Averages
Strong Sell

Analyst Ratings

8 Buy
0 Hold
0 Sell
Ratings:
8 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 10.60
(+534.99% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
H.C. Wainwright
Buy15.00+798.20%18.00MaintainJul 14, 2026
Leerink
Buy10.00+498.80%-New CoverageJul 13, 2026
TD Cowen
Buy---New CoverageJun 11, 2026
H.C. Wainwright
Buy18.00+977.84%-MaintainApr 28, 2026
H.C. Wainwright
Buy18.00+977.84%-New CoverageApr 27, 2026

Earnings

Latest Release
May 18, 2026
EPS / Forecast
-0.02 / -0.08
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

NGEN Income Statement

Compare NGEN to Peers and Sector

Metrics to compare
NGEN
Peers
Sector
Relationship
P/E Ratio
−5.9x−0.7x−0.4x
PEG Ratio
0.09−0.010.00
Price/Book
44.8x1.1x2.6x
Price / LTM Sales
-0.5x3.0x
Upside (Analyst Target)
-0.0%50.8%
Fair Value Upside
Unlock10.6%9.4%Unlock

NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company’s lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer’s disease; and NVG-300, which is in a preclinical model of ischemic stroke, amyotrophic lateral sclerosis, and confirmatory SCI study. NervGen Pharma Corp. has a licensing agreement with Case Western Reserve University to develop and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage. NervGen Pharma Corp. was incorporated in 2017 and is headquartered in Vancouver, Canada.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
15.36K0.01%25.65K
Other Institutional Investors
14.58M13.73%24.35M
Public Companies & Retail Investors
91.61M86.26%152.98M
Total
106.2M100.00%177.36M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
PFP Biosciences Holdings9.42%10,000,00016,700
The Paul And Phyllis Fireman Charitable Foundation2.71%2,879,1494,808

People Also Watch

2.64
CAST
+4.76%
0.512
SUGP
-0.97%
3.25
EMBC
-2.99%
6.89
TRDA
+0.29%
2.050
CMPX
-2.38%

FAQ

What Is the NervGen Pharma (NGEN) Stock Price Today?

The NervGen Pharma stock price today is 1.67 USD.

What Stock Exchange Does NervGen Pharma Trade On?

NervGen Pharma is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for NervGen Pharma?

The stock symbol for NervGen Pharma is "NGEN."

What Is the NervGen Pharma Market Cap?

As of today, NervGen Pharma market cap is 177.36M USD.

What Is NervGen Pharma's Earnings Per Share (TTM)?

The NervGen Pharma EPS (TTM) is -0.63.

When Is the Next NervGen Pharma Earnings Date?

NervGen Pharma will release its next earnings report on Aug 12, 2026.

From a Technical Analysis Perspective, Is NGEN a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has NervGen Pharma Stock Split?

NervGen Pharma has split 0 times.

How Many Employees Does NervGen Pharma Have?

NervGen Pharma has 10 employees.

What is the current trading status of NervGen Pharma (NGEN)?

As of Jul 18, 2026, NervGen Pharma (NGEN) is trading at a price of 1.67 USD, with a previous close of 1.67 USD. The stock has fluctuated within a day range of 1.59 USD to 1.70 USD, while its 52-week range spans from 1.59 USD to 6.30 USD.

What Is NervGen Pharma (NGEN) Price Target According to Analysts?

The average 12-month price target for NervGen Pharma is 10.60 USD, with a high estimate of 18 USD and a low estimate of 5.03 USD. 8 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +534.99% Upside potential.

What Is the NGEN Premarket Price?

NGEN's last pre-market stock price is 1.65 USD. The pre-market share volume is 3,530.00, and the stock has decreased by -0.02, or -1.20%.

What Is the NGEN After Hours Price?

NGEN's last after hours stock price is 1.69 USD, the stock has decreased by 0.02, or 1.20%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.